Cambrex Stock Price, News & Analysis (NYSE:CBM)

$49.65 0.50 (1.02 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$49.15
Today's Range$49.05 - $49.80
52-Week Range$42.55 - $62.95
Volume274,800 shs
Average Volume337,463 shs
Market Capitalization$1.63 billion
P/E Ratio15.66
Dividend YieldN/A
Beta2.26

About Cambrex (NYSE:CBM)

Cambrex logoCambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.49%
Quick Ratio2.53%

Price-To-Earnings

Trailing P/E Ratio15.66
Forward P/E Ratio16.72
P/E Growth1.11

Sales & Book Value

Annual Sales$490.64 million
Price / Sales3.32
Cash Flow$3.55 per share
Price / Cash13.98
Book Value$12.61 per share
Price / Book3.94

Profitability

Trailing EPS$3.00
Net Income$81.67 million
Net Margins18.79%
Return on Equity23.42%
Return on Assets16.19%

Miscellaneous

Employees1,295
Outstanding Shares32,780,000

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.08. The biotechnology company had revenue of $112.60 million for the quarter, compared to analyst estimates of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The company's revenue for the quarter was up 13.4% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. View Cambrex's Earnings History.

When will Cambrex make its next earnings announcement?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Cambrex.

Where is Cambrex's stock going? Where will Cambrex's stock price be in 2017?

3 analysts have issued 1-year price objectives for Cambrex's stock. Their forecasts range from $60.00 to $66.00. On average, they expect Cambrex's stock price to reach $62.33 in the next twelve months. View Analyst Ratings for Cambrex.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:

  • Steven Mark Klosk, President, Chief Executive Officer, Director (Age 60)
  • Tom George Vadaketh, Chief Financial Officer, Executive Vice President (Age 54)
  • Shawn P. Cavanagh, Chief Operating Officer, Executive Vice President (Age 50)
  • Gregory P. Sargen, Executive Vice President, Corporate Development and Strategy (Age 51)
  • Samantha M. Hanley, Vice President, General Counsel,Corporate Secretary (Age 39)
  • James G. Farrell, Vice President and Corporate Controller (Age 50)
  • Shlomo Yanai, Non-Executive Chairman of the Board (Age 64)
  • Gregory B. Brown M.D., Director (Age 64)
  • Rosina B. Dixon M.D., Independent Director (Age 74)
  • Claes Glassell, Independent Director (Age 65)

Who owns Cambrex stock?

Cambrex's stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (4.58%), Dimensional Fund Advisors LP (4.10%), American Capital Management Inc. (1.73%), Neumeier Poma Investment Counsel LLC (1.02%), Boston Partners (0.99%) and Ameriprise Financial Inc. (0.96%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Leon J Hendrix, Jr, Louis J Grabowsky, Peter G Tombros, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.

Who sold Cambrex stock? Who is selling Cambrex stock?

Cambrex's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Nationwide Fund Advisors, Bank of New York Mellon Corp, Principal Financial Group Inc., OxFORD Asset Management LLP, Neumeier Poma Investment Counsel LLC, Public Employees Retirement System of Ohio and Royce & Associates LP. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Who bought Cambrex stock? Who is buying Cambrex stock?

Cambrex's stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Brown Advisory Inc., JPMorgan Chase & Co., New York State Common Retirement Fund, American Capital Management Inc., Tributary Capital Management LLC, Sivik Global Healthcare LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Cambrex.

How do I buy Cambrex stock?

Shares of Cambrex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of Cambrex stock can currently be purchased for approximately $49.65.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.63 billion and generates $490.64 million in revenue each year. The biotechnology company earns $81.67 million in net income (profit) each year or $3.00 on an earnings per share basis. Cambrex employs 1,295 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (CBM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cambrex (NYSE:CBM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.33$62.33$65.67$63.40
Price Target Upside: 37.91% upside37.91% upside16.64% upside12.61% upside

Cambrex (NYSE:CBM) Consensus Price Target History

Price Target History for Cambrex (NYSE:CBM)

Cambrex (NYSE:CBM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017Craig HallumReiterated RatingBuy$70.00 -> $60.00N/AView Rating Details
2/6/2017StephensSet Price TargetBuy$61.00N/AView Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 -> $66.00N/AView Rating Details
2/11/2016Singular ResearchLower Price TargetBuy$63.00 -> $60.00N/AView Rating Details
2/1/2016SidotiInitiated CoverageBuy$60.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Cambrex (NYSE:CBM) Earnings History and Estimates Chart

Earnings by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE CBM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018N/AView Earnings Details
11/7/2017Q3 2017$0.47$0.55$108.44 million$112.60 millionViewN/AView Earnings Details
8/4/2017Q2 2017$0.76$0.76$136.82 million$134.55 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.51$0.68$99.05 million$105.01 millionViewListenView Earnings Details
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.53$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.60$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.29$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.32$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.05$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cambrex (NYSE:CBM) Earnings Estimates

2017 EPS Consensus Estimate: $2.88
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.48$0.51$0.50
Q2 20172$0.71$0.74$0.73
Q3 20172$0.48$0.52$0.50
Q4 20172$1.11$1.20$1.16
Q1 20181$0.47$0.47$0.47
Q2 20181$0.74$0.74$0.74
Q3 20181$0.56$0.56$0.56
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cambrex (NYSE:CBM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.48%
Insider Trades by Quarter for Cambrex (NYSE:CBM)
Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE CBM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Steven M KloskCEOSell4,000$54.96$219,840.00View SEC Filing  
9/1/2017Steven M KloskCEOSell12,000$51.53$618,360.00View SEC Filing  
8/1/2017Steven M KloskCEOSell12,000$61.39$736,680.00View SEC Filing  
7/3/2017Steven M KloskCEOSell12,000$59.66$715,920.00View SEC Filing  
6/12/2017Samantha HanleyVPSell14,000$57.56$805,840.00View SEC Filing  
6/6/2017Leon J Hendrix JrDirectorSell20,656$55.95$1,155,703.20View SEC Filing  
6/1/2017Steven M KloskCEOSell12,000$54.19$650,280.00View SEC Filing  
5/1/2017Steven M KloskCEOSell12,000$58.20$698,400.00View SEC Filing  
4/3/2017Steven M KloskCEOSell12,000$54.58$654,960.00View SEC Filing  
3/1/2017Steven M KloskCEOSell12,000$56.70$680,400.00View SEC Filing  
2/27/2017Shawn CavanaghCOOSell19,620$55.95$1,097,739.00View SEC Filing  
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.00View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.00View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.60View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.00View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.00View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.00View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.74View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.00View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.00View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.00View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.52View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.46View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.00View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.32View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.80View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.00View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.00View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.00View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.00View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.00View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.00View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cambrex (NYSE CBM) News Headlines

Source:
DateHeadline
ETFs with exposure to Cambrex Corp. : December 5, 2017ETFs with exposure to Cambrex Corp. : December 5, 2017
finance.yahoo.com - December 5 at 5:18 PM
Cambrex Co. (CBM) Receives Average Rating of "Hold" from AnalystsCambrex Co. (CBM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 4 at 1:56 AM
Analyzing Cambrex (CBM) and AMAG Pharmaceuticals (AMAG)Analyzing Cambrex (CBM) and AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - December 2 at 9:36 PM
Cambrex (CBM) vs. Its Rivals Head-To-Head ReviewCambrex (CBM) vs. Its Rivals Head-To-Head Review
www.americanbankingnews.com - December 1 at 11:36 PM
Analyzing Cambrex (CBM) & Corium International (CORI)Analyzing Cambrex (CBM) & Corium International (CORI)
www.americanbankingnews.com - December 1 at 11:38 AM
Critical Comparison: Pacira Pharmaceuticals (PCRX) vs. Cambrex (CBM)Critical Comparison: Pacira Pharmaceuticals (PCRX) vs. Cambrex (CBM)
www.americanbankingnews.com - November 30 at 11:42 AM
Head to Head Survey: Cambrex (CBM) and Its RivalsHead to Head Survey: Cambrex (CBM) and Its Rivals
www.americanbankingnews.com - November 29 at 3:28 AM
Comparing Cambrex (CBM) & Adamis Pharmaceuticals (ADMP)Comparing Cambrex (CBM) & Adamis Pharmaceuticals (ADMP)
www.americanbankingnews.com - November 28 at 3:34 PM
Cleantech Building Materials: Distribution and Offtake AgreementCleantech Building Materials: Distribution and Offtake Agreement
finance.yahoo.com - November 23 at 4:07 AM
Corporate News Blog - Puma Biotechnology’s 5-Year Analysis of Phase-III ExteNET Study Gets Published in ‘The Lancet Oncology’Corporate News Blog - Puma Biotechnology’s 5-Year Analysis of Phase-III ExteNET Study Gets Published in ‘The Lancet Oncology’
finance.yahoo.com - November 16 at 12:26 PM
Q4 2017 Earnings Estimate for Cambrex Corporation Issued By First Analysis (CBM)Q4 2017 Earnings Estimate for Cambrex Corporation Issued By First Analysis (CBM)
www.americanbankingnews.com - November 15 at 7:32 AM
First Analysis Comments on Cambrex Corporations Q2 2018 Earnings (CBM)First Analysis Comments on Cambrex Corporation's Q2 2018 Earnings (CBM)
www.americanbankingnews.com - November 14 at 10:30 AM
Cambrex Corporation (CBM) Given Consensus Rating of "Hold" by AnalystsCambrex Corporation (CBM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - November 9 at 1:34 AM
Cambrex Corp. (CBM) Tops Q3 EPS by 7c, Beats on Revenues; Offers FY17 EPS Mid-Point Below Consensus - StreetInsider.comCambrex Corp. (CBM) Tops Q3 EPS by 7c, Beats on Revenues; Offers FY17 EPS Mid-Point Below Consensus - StreetInsider.com
www.streetinsider.com - November 8 at 8:02 PM
Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa FacilityCambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility
finance.yahoo.com - November 8 at 8:02 PM
Edited Transcript of CBM earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of CBM earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 12:58 AM
Cambrex Reaffirms 2017 OutlookCambrex Reaffirms 2017 Outlook
www.rttnews.com - November 7 at 7:56 PM
Cambrex Corporation to Host Earnings CallCambrex Corporation to Host Earnings Call
finance.yahoo.com - November 7 at 7:56 PM
Cambrex Reports Third Quarter 2017 Financial ResultsCambrex Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 7:56 PM
Cambrex posts 3Q profitCambrex posts 3Q profit
finance.yahoo.com - November 7 at 7:56 PM
Will Cambrex Corporation’s (CBM) Earnings Grow In The Year Ahead?Will Cambrex Corporation’s (CBM) Earnings Grow In The Year Ahead?
finance.yahoo.com - November 7 at 7:56 PM
Cambrex Corporation (CBM) Issues Quarterly  Earnings Results, Beats Expectations By $0.07 EPSCambrex Corporation (CBM) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 7 at 12:17 PM
Cambrex Corp. (CBM) Appoints Gregory Brown to Board - StreetInsider.comCambrex Corp. (CBM) Appoints Gregory Brown to Board - StreetInsider.com
www.streetinsider.com - November 3 at 5:41 PM
Cambrex to Present at the Stephens Fall Investment ConferenceCambrex to Present at the Stephens Fall Investment Conference
feeds.benzinga.com - November 3 at 12:58 PM
Gregory B. Brown MD Appointed to the Board of Directors of Cambrex Corporation - GlobeNewswire (press release)Gregory B. Brown MD Appointed to the Board of Directors of Cambrex Corporation - GlobeNewswire (press release)
globenewswire.com - November 3 at 8:08 AM
Gregory B. Brown M.D. Appointed to the Board of Directors of Cambrex CorporationGregory B. Brown M.D. Appointed to the Board of Directors of Cambrex Corporation
finance.yahoo.com - November 3 at 8:08 AM
Cambrex to Announce Third Quarter 2017 Financial Results on November 7, 2017Cambrex to Announce Third Quarter 2017 Financial Results on November 7, 2017
feeds.benzinga.com - October 31 at 11:15 AM
Cambrex Corporation (CBM) Scheduled to Post Earnings on ThursdayCambrex Corporation (CBM) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - October 26 at 3:26 AM
Cambrex Adds Large Scale Manufacturing Capacity at Its Charles City, Iowa FacilityCambrex Adds Large Scale Manufacturing Capacity at Its Charles City, Iowa Facility
finance.yahoo.com - October 23 at 3:45 PM
Cleantech Building Materials: Board and senior personnel changes, grant of options and opening of new Shanghai officeCleantech Building Materials: Board and senior personnel changes, grant of options and opening of new Shanghai office
finance.yahoo.com - October 20 at 6:43 PM
Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : October 18, 2017Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : October 18, 2017
finance.yahoo.com - October 18 at 6:17 PM
Cambrex Corporation (CBM) Receives Average Rating of "Hold" from AnalystsCambrex Corporation (CBM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 15 at 2:28 AM
Cambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan SiteCambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan Site
finance.yahoo.com - October 12 at 5:46 PM
Tecan Group AG: Tecan initiates succession process for the Board of DirectorsTecan Group AG: Tecan initiates succession process for the Board of Directors
www.finanznachrichten.de - October 6 at 5:15 PM
Tecan initiates succession process for the Board of DirectorsTecan initiates succession process for the Board of Directors
globenewswire.com - October 6 at 5:15 PM
Analyzing Cadence Pharmaceuticals (CADX) & Cambrex Corporation (CBM)Analyzing Cadence Pharmaceuticals (CADX) & Cambrex Corporation (CBM)
www.americanbankingnews.com - October 6 at 6:24 AM
Cambrex Corporation (CBM) CEO Sells $219,840.00 in StockCambrex Corporation (CBM) CEO Sells $219,840.00 in Stock
www.americanbankingnews.com - October 3 at 11:14 PM
Cambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : September 27, 2017Cambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : September 27, 2017
finance.yahoo.com - October 2 at 3:32 PM
Cambrex Corp. – Value Analysis (NYSE:CBM) : September 28, 2017Cambrex Corp. – Value Analysis (NYSE:CBM) : September 28, 2017
finance.yahoo.com - October 2 at 3:32 PM
Cleantech Building Materials: Board change and appointment of new Chief Financial OfficerCleantech Building Materials: Board change and appointment of new Chief Financial Officer
finance.yahoo.com - October 2 at 3:32 PM
Cambrex Opens Large Scale API Manufacturing Facility and Invests ... - GlobeNewswire (press release)Cambrex Opens Large Scale API Manufacturing Facility and Invests ... - GlobeNewswire (press release)
globenewswire.com - September 27 at 5:37 PM
Cambrex Opens Large Scale API Manufacturing Facility and Invests in Supporting Waste Water Treatment Plant at Its Karlskoga, Sweden SiteCambrex Opens Large Scale API Manufacturing Facility and Invests in Supporting Waste Water Treatment Plant at Its Karlskoga, Sweden Site
finance.yahoo.com - September 26 at 8:33 AM
Cambrex Corporation (CBM) Given Consensus Recommendation of "Hold" by AnalystsCambrex Corporation (CBM) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 20 at 2:30 AM
Is Cambrex Corporation (CBM) a Suitable Value Stock? - NasdaqIs Cambrex Corporation (CBM) a Suitable Value Stock? - Nasdaq
www.nasdaq.com - September 19 at 10:01 PM
Is Cambrex Corporation (CBM) a Suitable Value Stock?Is Cambrex Corporation (CBM) a Suitable Value Stock?
finance.yahoo.com - September 19 at 5:01 PM
Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceCambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
feeds.benzinga.com - September 18 at 11:19 AM
Cambrex Corporation (CBM) versus Marinus Pharmaceuticals (MRNS) Financial SurveyCambrex Corporation (CBM) versus Marinus Pharmaceuticals (MRNS) Financial Survey
www.americanbankingnews.com - September 9 at 10:26 AM
Cambrex Corporation (CBM) Presents At Bairds 2017 Global Healthcare Conference - SlideshowCambrex Corporation (CBM) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 3:26 AM
Cambrex Corporation (CBM) Presents At 2017 Wells Fargo Healthcare Conference - SlideshowCambrex Corporation (CBM) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 5:04 PM
Insider Selling: Cambrex Corporation (CBM) CEO Sells 12,000 Shares of StockInsider Selling: Cambrex Corporation (CBM) CEO Sells 12,000 Shares of Stock
www.americanbankingnews.com - September 5 at 7:46 PM

SEC Filings

Cambrex (NYSE:CBM) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cambrex (NYSE CBM) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.